James Daniel Doorley, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurofibromatoses | 2 | 2021 | 303 | 0.710 |
Why?
|
Emotions | 4 | 2020 | 2758 | 0.630 |
Why?
|
Receptors, Dopamine D4 | 2 | 2016 | 168 | 0.630 |
Why?
|
Neurofibromatosis 2 | 1 | 2021 | 387 | 0.580 |
Why?
|
Neurofibromatosis 1 | 1 | 2021 | 561 | 0.530 |
Why?
|
Opioid-Related Disorders | 3 | 2024 | 2188 | 0.460 |
Why?
|
Orthopedics | 1 | 2022 | 906 | 0.440 |
Why?
|
Anxiety | 6 | 2023 | 4668 | 0.400 |
Why?
|
Affect | 1 | 2020 | 1494 | 0.390 |
Why?
|
Sex Offenses | 1 | 2016 | 355 | 0.390 |
Why?
|
Suicidal Ideation | 2 | 2017 | 1467 | 0.320 |
Why?
|
Suicide, Attempted | 1 | 2016 | 1413 | 0.280 |
Why?
|
Minisatellite Repeats | 2 | 2016 | 162 | 0.250 |
Why?
|
Resilience, Psychological | 2 | 2021 | 807 | 0.210 |
Why?
|
Pain Measurement | 2 | 2022 | 3576 | 0.190 |
Why?
|
Sports Medicine | 1 | 2024 | 239 | 0.190 |
Why?
|
Feasibility Studies | 2 | 2022 | 5306 | 0.180 |
Why?
|
Technology | 1 | 2022 | 296 | 0.170 |
Why?
|
Analgesics, Opioid | 3 | 2024 | 3837 | 0.160 |
Why?
|
Professional Role | 1 | 2022 | 314 | 0.160 |
Why?
|
Panic Disorder | 1 | 2021 | 613 | 0.150 |
Why?
|
Thiazoles | 2 | 2015 | 1529 | 0.140 |
Why?
|
Hospitalization | 2 | 2017 | 10816 | 0.140 |
Why?
|
Psychiatric Department, Hospital | 1 | 2016 | 133 | 0.130 |
Why?
|
Polymorphism, Genetic | 2 | 2016 | 4249 | 0.120 |
Why?
|
Avoidance Learning | 1 | 2016 | 248 | 0.120 |
Why?
|
Touch | 1 | 2016 | 313 | 0.120 |
Why?
|
Adult | 12 | 2024 | 223305 | 0.110 |
Why?
|
Piperazines | 2 | 2015 | 2547 | 0.110 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 305 | 0.110 |
Why?
|
Athletic Injuries | 1 | 2024 | 1244 | 0.110 |
Why?
|
Crime Victims | 1 | 2017 | 347 | 0.100 |
Why?
|
Depression | 4 | 2024 | 8225 | 0.100 |
Why?
|
Interpersonal Relations | 2 | 2017 | 1432 | 0.100 |
Why?
|
Humans | 25 | 2024 | 766812 | 0.100 |
Why?
|
Aggression | 1 | 2017 | 748 | 0.100 |
Why?
|
Psychomotor Agitation | 1 | 2014 | 307 | 0.100 |
Why?
|
Health Personnel | 2 | 2022 | 3384 | 0.100 |
Why?
|
Peer Group | 1 | 2017 | 702 | 0.090 |
Why?
|
Family Characteristics | 1 | 2016 | 1002 | 0.090 |
Why?
|
Qualitative Research | 1 | 2022 | 3138 | 0.090 |
Why?
|
Psychometrics | 1 | 2020 | 3060 | 0.090 |
Why?
|
Mood Disorders | 1 | 2017 | 1127 | 0.090 |
Why?
|
Depressive Disorder, Major | 2 | 2021 | 4810 | 0.090 |
Why?
|
Communication | 2 | 2024 | 3905 | 0.090 |
Why?
|
Quality of Life | 2 | 2021 | 13476 | 0.080 |
Why?
|
Complementary Therapies | 1 | 2013 | 486 | 0.080 |
Why?
|
Adaptation, Psychological | 1 | 2020 | 2662 | 0.080 |
Why?
|
Catastrophization | 2 | 2023 | 352 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2022 | 3618 | 0.080 |
Why?
|
Adolescent Behavior | 1 | 2017 | 1185 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2022 | 3266 | 0.080 |
Why?
|
Male | 13 | 2024 | 364154 | 0.070 |
Why?
|
Attitude of Health Personnel | 1 | 2022 | 3927 | 0.070 |
Why?
|
Mental Health | 1 | 2022 | 3269 | 0.070 |
Why?
|
Goals | 2 | 2024 | 717 | 0.070 |
Why?
|
Female | 12 | 2024 | 396532 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6329 | 0.070 |
Why?
|
Pain | 1 | 2021 | 5098 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26309 | 0.060 |
Why?
|
Substance-Related Disorders | 2 | 2024 | 4421 | 0.060 |
Why?
|
Middle Aged | 6 | 2024 | 223267 | 0.050 |
Why?
|
Athletic Performance | 1 | 2024 | 112 | 0.050 |
Why?
|
Cytidine Monophosphate | 1 | 2022 | 11 | 0.050 |
Why?
|
Antidepressive Agents | 1 | 2015 | 2903 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2014 | 3078 | 0.050 |
Why?
|
Depressive Disorder | 1 | 2013 | 3715 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2013 | 3429 | 0.040 |
Why?
|
Individuality | 1 | 2020 | 303 | 0.040 |
Why?
|
Arousal | 1 | 2024 | 1174 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2020 | 1001 | 0.040 |
Why?
|
Anxiety Disorders | 2 | 2021 | 2743 | 0.030 |
Why?
|
Adolescent | 4 | 2020 | 88902 | 0.030 |
Why?
|
Friends | 1 | 2016 | 150 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27158 | 0.030 |
Why?
|
United States | 1 | 2022 | 72945 | 0.030 |
Why?
|
Aged | 3 | 2022 | 171344 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 18076 | 0.030 |
Why?
|
Attention | 1 | 2024 | 2413 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2020 | 81657 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2015 | 12430 | 0.020 |
Why?
|
Heterozygote | 1 | 2015 | 2795 | 0.020 |
Why?
|
Exercise Therapy | 1 | 2013 | 935 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2016 | 2645 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2020 | 4526 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2015 | 6020 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2015 | 65286 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20146 | 0.010 |
Why?
|
Internship and Residency | 1 | 2022 | 5943 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 8045 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 59548 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 59939 | 0.010 |
Why?
|